FOLH1 and neoplasm: While FAPI grants a wider spectrum of tumor targeting potential compared to conventional radiotracers that recognize tumor cell-specific biomarkers, for example somatostatin receptor subtype-2 targeting DOTATATE and prostate specific membrane antigen targeting PSMA-617; it can be a double-edged sword.